$3.32 $0.03 (0.0%)

04:00 PM EDT on 06/26/19

Capricor Therapeutics Inc (NASDAQ:CAPR)

CAPS Rating: 2 out of 5

Current Price $3.32 Mkt Cap $16.5M
Open $3.30 P/E Ratio 0.00
Prev. Close $3.32 Div. (Yield) $0.00 (0.0%)
Daily Range $3.25 - $3.42 Volume 12,011
52-Wk Range $2.60 - $7.50 Avg. Daily Vol.


How do you think NASDAQ:CAPR will perform against the market?

Add Stock to CAPS Watchlist

All Players

12 Outperform
4 Underperform

All-Star Players

6 Outperform
4 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:CAPR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.79)
Submitted June 11, 2015

Capricor is a low float, microcap stem cell biotech so it should be clear that I'm looking at this company as a short-term trade and not a long term bet on an FDA approved, successfully commercialized therapeutic. Portefeuille forced me to add the… More

SmartAce (99.97)
Submitted March 23, 2015

You ever say the wrong thing? Like maybe you pass someone you know on the street, unexpectedly, and as you go by, you're trying to play it cool, but you screw it up? And you accidentally answer the question that you thought they were going to ask you… More



Fools bullish on NASDAQ:CAPR are also bullish on:

Fools bearish on NASDAQ:CAPR are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CAPR.


Member Avatar Bigsef77 (68.06) Submitted: 1/31/2019 10:04:37 AM : Outperform Start Price: $0.93 NASDAQ:CAPR Score: +234.12

Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
GlobeNewswire•January 22, 2019

FDA Provides Positive Feedback on Design for HOPE-2 Clinical Trial

LOS ANGELES, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR), a clinical-stage biotechnology company, today announced that it had positive outcomes in its comprehensive multidisciplinary meeting with the U.S. Food and Drug Administration (FDA) regarding development of the company’s novel cell therapy candidate, CAP-1002, to treat Duchenne muscular dystrophy.

Capricor met with the FDA in December 2018, as part of the expedited review afforded under the Regenerative Medicine Advanced Therapy (RMAT) designation which the FDA granted to CAP-1002 in February 2018. The FDA grants the RMAT designation to investigational regenerative medicine therapies intended to treat a serious condition and for which preliminary clinical evidence indicates a potential to address unmet medical needs for that condition.

During the meeting discussion and in subsequent meeting minutes, Capricor asked whether the FDA would agree to its current clinical trial, HOPE-2, serving as the registration study, if HOPE-2 provides evidence that CAP-1002 is safe and effective in treating Duchenne muscular dystrophy. The FDA advised Capricor to request an end of phase meeting after completion of the trial to determine whether HOPE-2 could serve as the registration study.


Find the members with the highest scoring picks in CAPR.

Score Leader


Bigsef77 (68.06) Score: +234.12

The Score Leader is the player with the highest score across all their picks in CAPR.

Member Name Member
Call Time
Score Commentary
Bigsef77 68.06 5/18/2017 11/2/2018 Outperform 5Y $0.93 +256.99% +22.87% +234.12 1 Comment
drugtrader 93.02 10/8/2018 Outperform 5Y $1.06 +213.21% +1.24% +211.97 0 Comment
jeepdrew222 68.38 9/4/2018 Outperform 5Y $1.23 +169.92% +0.26% +169.66 0 Comment
ColinBalsbaugh 32.16 5/30/2018 Outperform 5Y $1.31 +153.44% +7.43% +146.00 0 Comment
TrevorCarson 24.19 7/20/2018 Outperform 5Y $1.33 +149.62% +3.87% +145.75 0 Comment
efarev 98.68 11/24/2017 Outperform 5Y $2.12 +56.60% +11.63% +44.97 0 Comment
zzlangerhans 99.79 10/2/2017 Underperform 1Y $3.20 +3.75% +15.55% +11.80 0 Comment
johnnyrocku 99.90 10/9/2017 Underperform 5Y $2.85 +16.49% +14.13% -2.36 0 Comment
FSaucy 98.99 8/21/2015 Outperform NS $3.89 -14.65% +46.11% -60.76 0 Comment
Chemnerd 62.43 8/10/2015 Outperform 5Y $4.61 -27.98% +38.86% -66.84 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CAPR.